The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.92

Today's change+0.07 +2.46%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.92

Today's change+0.07 +2.46%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

PDL BioPharma Inc up sharply

PDL BioPharma Inc closed up sharply Friday, rallying (U.S.)$0.07 or 2.46% to (U.S.)$2.92. Over the last five days, shares have lost 7.01% and are down 17.51% for the last year to date. This security has underperformed the S&P 500 by 50.60% during the last year.

Key company metrics

  • Open(U.S.) $2.85
  • Previous close(U.S.) $2.85
  • High(U.S.) $2.96
  • Low(U.S.) $2.83
  • Bid / Ask-- / --
  • YTD % change-17.51%
  • Volume2,695,705
  • Average volume (10-day)2,333,742
  • Average volume (1-month)2,228,853
  • Average volume (3-month)3,354,262
  • 52-week range(U.S.) $2.58 to (U.S.) $7.43
  • Beta0.68
  • Trailing P/E1.74×
  • P/E 1 year forward1.51×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.20
  • Dividend yield6.85%
  • Trailing EPS(U.S.) $1.68
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+54.26%

Based on its net profit margin of 54.26%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue125138150117
Total other revenue--------
Total revenue125138150117
Gross profit--------
Total cost of revenue--------
Total operating expense87818
Selling / general / administrative87818
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income11613114299
Interest income (expense), net non-operating-6-7-9-9
Gain (loss) on sale of assets--------
Other--------
Income before tax11012413490
Income after tax69788455
Income tax, total41454935
Net income69788455
Total adjustments to net income--------
Net income before extra. items69788455
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items69788455
Inc. avail. to common incl. extra. items69788455
Diluted net income69788555
Dilution adjustment----10
Diluted weighted average shares164165170197
Diluted EPS excluding extraordinary itemsvalue per share0.420.470.500.28
Dividends per sharevalue per share0.150.150.150.15
Diluted normalized EPSvalue per share0.420.470.500.28